ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and toll-like receptors"

  • Abstract Number: 301 • 2017 ACR/ARHP Annual Meeting

    MiR-221-3p Overexpression Impairs Anti-Inflammatory Activity of TLR4-Stimulated M2-Macrophages

    Lilian Quero1,2, Andre Tiaden1,2 and Diego Kyburz2,3, 1Department of Biomedicine, Experimental Rheumatology, University of Basel, Basel, Switzerland, 2Rheumatology, University Hospital Basel, Basel, Switzerland, 3Department of Biomedicine, Experimental Rheumatology, University of Basel, 4051 Basel, Switzerland

    Background/Purpose: MicroRNAs (miRNAs) have been shown to contribute to the inflammatory response in rheumatoid arthritis (RA) and several of these miRNAs have been found to…
  • Abstract Number: 1368 • 2015 ACR/ARHP Annual Meeting

    PMN Reactivity Contribute to Acute Onset Joint Inflammation By Increasing CXCL8 Production in Joints of RA Patients with Anti-Collagen II Antibodies

    Vivek Anand Manivel1, Azita Sohrabian2 and Johan Rönnelid3,4, 1Immunology, Genetics and Pathology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 2Department of Immunology Genetics and Pathology,Uppsala University, Uppsala, Sweden, 3Department of Immunology, Genetics and Pathology,Uppsala University, Uppsala, Sweden, 44Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: RA patients with antibodies against collagen type II (CII) have a distinct acute onset RA phenotype, associated with cytokine induction by surface-bound anti-CII IC…
  • Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting

    Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine

    Emmanuel Monnet1, Limin Shang1, Geneviève Lapeyre1, Kathy De Graaf2, Eric Hatterer1, Gaelle Wambiekele1, Walter Ferlin1, Philippe Jacqmin3, Cem Gabay4, Jeremy Sokolove5, Simon Jones6, Ernest H. Choy7, Iain B. McInnes8, Marie Kosco-Vilbois1 and Cristina De Min1, 1NovImmune S.A., Geneva, Switzerland, 2Novimmune S.A., Geneva, Switzerland, 3SGS Exprimo, Mechelen, Belgium, 4Rheumatology, Geneva University Hospital, Geneva, Switzerland, 5Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6Cardiff Institute of Infection & Immunity, Cardiff, United Kingdom, 7Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 8Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…
  • Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting

    Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients

    Jacob Sode1,2,3, Ulla Vogel4, Steffen Bank5,6, Paal Skytt Andersen7, Merete Lund Hetland8,9, Henning Locht3, Niels H. H. Heegaard10,11 and Vibeke Andersen1,5,12,13, 1Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, 2Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, 3Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, 4National Research Centre for the Working Environment, Copenhagen, Denmark, 5Medical Department, Viborg Regional Hospital, Viborg, Denmark, 6Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, 7Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 9Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 10Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 11Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, 12Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, 13Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark

    Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
  • Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting

    Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression

    Marshall Davis1, Tricia LeVan2, Fang Yu3, Harlan Sayles4, Jeremy Sokolove5, William H. Robinson6, Kaleb Michaud7, Geoffrey M Thiele8 and Ted R. Mikuls4, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Univ of Nebraska Med Ctr, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 6VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7National Data Bank for Rheumatic Diseases, Wichita, KS, 8Omaha VA and the University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA).  In this study,…
  • Abstract Number: 1195 • 2014 ACR/ARHP Annual Meeting

    Activation of the nlrp3 Inflammasome By an Endogenous TLR2 Ligand in Rheumatoid Arthritis

    Mary Connolly, Trudy McGarry, Monika Biniecka, Douglas J. Veale and Ursula Fearon, Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland

    Background/Purpose: The inflammasome is a large multiprotein complex which plays a key role in innate immunity by mediating the production of pro-inflammatory cytokines interleukin-1β (IL-1β)…
  • Abstract Number: 1044 • 2014 ACR/ARHP Annual Meeting

    Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

    Trudy McGarry1, Mary Connolly1, Rebecca C. Coll2, Avril A. B. Robertson3, Matthew A. Cooper3, Luke A. O'Neill2, Douglas J. Veale1 and Ursula Fearon1, 1Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 2Inflammation Research, School of Biochemistry and Immunology, Dublin, Ireland, 3The University of Queensland, Brisbane, Australia

    Background/Purpose: The NLRP3 inflammasome is a multi-protein complex activated in response to environmental pathogens. This results in caspase-1-dependant cleavage of pro-IL-1β and IL-18 to their…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology